Zoetis Inc. has received Health Canada approval for Portela™ (relfovetmab injection), a new monoclonal antibody therapy designed to alleviate pain associated with osteoarthritis in cats. Portela provides three months of pain relief with a single injection and targets nerve growth factor (NGF), a key contributor to osteoarthritis pain and inflammation. The approval follows a nine-month field trial in Europe, where Portela demonstrated effectiveness and was well tolerated, including in cats with early-stage kidney disease. Zoetis plans to make Portela commercially available in Canada and the European Union in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251204633153) on December 05, 2025, and is solely responsible for the information contained therein.